Indivior (NASDAQ:INDV) Cut to Buy at Wall Street Zen

Key Points

• Wall Street Zen downgraded Indivior from “strong buy” to “buy,” while the broader analyst consensus remains “Buy,” with an average price target of $46.40.
• Indivior reported quarterly EPS of $1.32, beating the $1.06 consensus estimate, and revenue of $356 million versus expectations of $329.35 million.
• Shares opened at $35.37, near their 50-day and 200-day moving averages; institutional investors and hedge funds own approximately 60.33% of the company.

Indivior (NASDAQ:INDV - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a report released on Saturday, Wall Street Zen reports.

Several other research firms also recently issued reports on INDV. Barclays upped their price objective on shares of Indivior from $43.00 to $45.00 and gave the stock an "overweight" rating in a report on Wednesday. Zacks Research upgraded shares of Indivior from a "hold" rating to a "strong-buy" rating in a report on Friday, October 2nd. Weiss Ratings lowered shares of Indivior from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, September 24th. Finally, Craig Hallum restated a "buy" rating and set a $53.00 price target on shares of Indivior in a report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $46.40.

Indivior Stock Performance

INDV opened at $35.37 on Friday. The business has a 50 day moving average price of $35.20 and a 200 day moving average price of $35.62. Indivior has a twelve month low of $27.68 and a twelve month high of $42.81. The firm has a market cap of $4.17 billion, a P/E ratio of 8.29 and a beta of 0.87.

Indivior (NASDAQ:INDV - Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.06 by $0.26. Indivior had a negative return on equity of 418.04% and a net margin of 32.75%. The firm had revenue of $356.00 million during the quarter, compared to analysts' expectations of $329.35 million. As a group, analysts anticipate that Indivior will post 3.66 earnings per share for the current fiscal year.

Insider Activity

In related news, CAO Woodrow D. Anderson acquired 1,500 shares of the business's stock in a transaction dated Thursday, August 27th. The stock was acquired at an average price of $35.69 per share, with a total value of $53,535.00. Following the completion of the transaction, the chief accounting officer owned 27,638 shares of the company's stock, valued at approximately $986,400.22. This represents a 5.74% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.74% of the company's stock.

Institutional Investors Weigh In On Indivior

A number of institutional investors have recently added to or reduced their stakes in the company. Two Seas Capital LP raised its stake in shares of Indivior by 5.5% in the third quarter. Two Seas Capital LP now owns 3,671,072 shares of the company's stock valued at $131,608,000 after purchasing an additional 191,579 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in Indivior by 129.8% during the third quarter. Assenagon Asset Management S.A. now owns 3,540,344 shares of the company's stock worth $126,921,000 after buying an additional 1,999,416 shares in the last quarter. Newtyn Management LLC acquired a new stake in Indivior during the second quarter worth $53,577,000. Hennion & Walsh Asset Management Inc. acquired a new stake in Indivior during the second quarter worth $14,781,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Indivior during the second quarter worth $7,988,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Indivior Company Profile

Indivior PLC NASDAQ: INDV is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company's principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.